Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb 25;16(1):204.
doi: 10.1186/ar4493.

Biology of platelet-rich plasma and its clinical application in cartilage repair

Review

Biology of platelet-rich plasma and its clinical application in cartilage repair

Xuetao Xie et al. Arthritis Res Ther. .

Abstract

Platelet-rich plasma (PRP) is an autologous concentrated cocktail of growth factors and inflammatory mediators, and has been considered to be potentially effective for cartilage repair. In addition, the fibrinogen in PRP may be activated to form a fibrin matrix to fill cartilage lesions, fulfilling the initial requirements of physiological wound healing. The anabolic, anti-inflammatory and scaffolding effects of PRP based on laboratory investigations, animal studies, and clinical trials are reviewed here. In vitro, PRP is found to stimulate cell proliferation and cartilaginous matrix production by chondrocytes and adult mesenchymal stem cells (MSCs), enhance matrix secretion by synoviocytes, mitigate IL-1β-induced inflammation, and provide a favorable substrate for MSCs. In preclinical studies, PRP has been used either as a gel to fill cartilage defects with variable results, or to slow the progression of arthritis in animal models with positive outcomes. Findings from current clinical trials suggest that PRP may have the potential to fill cartilage defects to enhance cartilage repair, attenuate symptoms of osteoarthritis and improve joint function, with an acceptable safety profile. Although current evidence appears to favor PRP over hyaluronan for the treatment of osteoarthritis, the efficacy of PRP therapy remains unpredictable owing to the highly heterogeneous nature of reported studies and the variable composition of the PRP preparations. Future studies are critical to elucidate the functional activity of individual PRP components in modulating specific pathogenic mechanisms.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Principal components and potential effects and actions of PRP. PRP contains growth factors that stimulate cellular anabolism, inflammatory mediators and modulators that exert anti-inflammatory effects, and fibrinogen that acts as a biomaterial scaffold. PRP, platelet-rich plasma.
Figure 2
Figure 2
Scanning electron microscopy of MSC-laden PRP scaffolds. MSCs adhere to the PRP fibrin fibers (adhesion sites indicated by arrows in B). A) low magnification; B) high magnification. MSC, mesenchymal stem cell; PRP, platelet-rich plasma.

Similar articles

Cited by

References

    1. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;16:780–785. doi: 10.2106/JBJS.F.00222. - DOI - PubMed
    1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F. National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;16:26–35. doi: 10.1002/art.23176. - DOI - PMC - PubMed
    1. Fortier LA, Hackett CH, Cole BJ. The effects of platelet-rich plasma on cartilage: basic science and clinical application. Oper Tech Sports Med. 2011;16:154–159. doi: 10.1053/j.otsm.2011.03.004. - DOI
    1. Andia I, Sanchez M, Maffulli N. Joint pathology and platelet-rich plasma therapies. Expert Opin Biol Ther. 2012;16:7–22. doi: 10.1517/14712598.2012.632765. - DOI - PubMed
    1. Italiano JE Jr, Shivdasani RA. Megakaryocytes and beyond: the birth of platelets. J Thromb Haemost. 2003;16:1174–1182. doi: 10.1046/j.1538-7836.2003.00290.x. - DOI - PubMed

Publication types